Healthcare provider profile · identity verified

Ryan Wu, MD

Family Practice · LIVERMORE, CA · NPI 1598843641

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	449	143
Levothyroxine Sodium	Levothyroxine Sodium	269	84
Amlodipine Besylate	Amlodipine Besylate	226	77
Losartan Potassium	Losartan Potassium	203	68
Lisinopril	Lisinopril	192	68
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	166	30
Metoprolol Tartrate	Metoprolol Tartrate	138	40
Atenolol	Atenolol	109	33
Tamsulosin Hcl	Tamsulosin Hcl	106	33
Hydrochlorothiazide	Hydrochlorothiazide	102	35
Terazosin Hcl	Terazosin Hcl	102	34
Fluticasone Propionate	Fluticasone Propionate	98	36
Allopurinol	Allopurinol	96	32
Alvesco	Ciclesonide	93	20
Famotidine	Famotidine	93	42
Pantoprazole Sodium	Pantoprazole Sodium	85	29
Simvastatin	Simvastatin	84	26
Albuterol Sulfate Hfa	Albuterol Sulfate	83	46
Furosemide	Furosemide	82	33
Oxycodone Hcl	Oxycodone Hcl	82	suppressed
Gabapentin	Gabapentin	81	25
Ibuprofen	Ibuprofen	78	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	78	32
Metoprolol Succinate	Metoprolol Succinate	72	29
Ozempic	Semaglutide	69	14
Montelukast Sodium	Montelukast Sodium	67	19
Metformin Hcl Er	Metformin Hcl	66	30
Ondansetron Odt	Ondansetron	66	suppressed
Metformin Hcl	Metformin Hcl	65	25
Omeprazole	Omeprazole	63	25
Carvedilol	Carvedilol	62	20
Trazodone Hcl	Trazodone Hcl	58	22
Jardiance	Empagliflozin	55	22
Doxycycline Monohydrate	Doxycycline Monohydrate	54	24
Morphine Sulfate Er	Morphine Sulfate	50	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	49	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	49	18
Sertraline Hcl	Sertraline Hcl	45	17
Acetaminophen-Codeine	Acetaminophen With Codeine	43	suppressed
Glipizide	Glipizide	43	17
Triamcinolone Acetonide	Triamcinolone Acetonide	43	30
Alendronate Sodium	Alendronate Sodium	38	12
Tramadol Hcl	Tramadol Hcl	38	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	37	12
Amoxicillin	Amoxicillin	36	21
Fluoxetine Hcl	Fluoxetine Hcl	36	12
Lovastatin	Lovastatin	34	12
Azelastine Hcl	Azelastine Hcl	33	11
Finasteride	Finasteride	33	suppressed
Fluocinonide	Fluocinonide	32	24
Temazepam	Temazepam	32	suppressed
Lactulose	Lactulose	31	suppressed
Naproxen	Naproxen	31	11
Ipratropium Bromide	Ipratropium Bromide	30	suppressed
Prednisone	Prednisone	30	17
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	12
Warfarin Sodium	Warfarin Sodium	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	27	suppressed
Acyclovir	Acyclovir	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Hydrocortisone	Hydrocortisone	26	15
Cefadroxil	Cefadroxil	25	21
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Metronidazole	Metronidazole	25	12
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Lorazepam	Lorazepam	24	13
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Baclofen	Baclofen	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	23	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	22	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	17
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Fentanyl	Fentanyl	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Lidocaine	Lidocaine	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	17	suppressed
Eliquis	Apixaban	16	suppressed
Humulin N	Insulin Nph Human Isophane	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Primidone	Primidone	16	suppressed
Azithromycin	Azithromycin	15	11
Clobetasol Propionate	Clobetasol Propionate	15	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	14	14
Humalog	Insulin Lispro	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Clonazepam	Clonazepam	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Fluorouracil	Fluorouracil	13	13
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Diazepam	Diazepam	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Dextroamphetamine Sulfate Er	Dextroamphetamine Sulfate	11	suppressed
Retin-A	Tretinoin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error